Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic r...
Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma
About this item
Full title
Author / Creator
Publisher
Singapore: Springer Singapore
Journal title
Language
English
Formats
Publication information
Publisher
Singapore: Springer Singapore
Subjects
More information
Scope and Contents
Contents
Background
The aim of this study was to compare the efficacy and safety of nivolumab as second-line and later-line (third-line or thereafter) therapy in metastatic renal cell carcinoma (mRCC).
Methods
Sixty-seven patients who received nivolumab after the failure of at least one molecular-targeted therapy were evaluated. The patients were d...
Alternative Titles
Full title
Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2329739515
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2329739515
Other Identifiers
ISSN
1341-9625
E-ISSN
1437-7772
DOI
10.1007/s10147-019-01605-9
